Finasteride/tamsulosin - GL PharmTech

Drug Profile

Finasteride/tamsulosin - GL PharmTech

Alternative Names: GL2701; Tamsulosin/finasteride

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GL PharmTech
  • Class Androstenes; Antiandrogens; Antineoplastics; Azasteroids; Small molecules; Sulfonamides
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists; Cholestenone 5-alpha reductase inhibitors; Testosterone antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Benign prostatic hyperplasia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Benign-prostatic-hyperplasia(In volunteers) in South Korea (PO, Capsule)
  • 12 Mar 2014 GL PharmTech announces intention to submit NDA in 2017
  • 29 Feb 2012 The Korea University Anam Hospital & GL PharmTech complete a phase I trial in Healthy volunteers in South Korea (NCT01829893)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top